Denver, Colorado – CODX (NASDAQ:CODX) is making a strategic push to scale its global diagnostics platform, announcing a major expansion of its commercial and distribution footprint across South Asia through its joint venture, CoSara Diagnostics.
The agreement significantly broadens CoSara’s reach beyond India into Bangladesh, Pakistan, Nepal, and Sri Lanka, increasing the region’s total addressable market to an estimated $13 billion. The move is designed to lay the groundwork for future commercialization of the company’s molecular diagnostics portfolio, including its PCR Pro point-of-care platform and SARAGENE® product line, pending regulatory approvals in each market.
Rather than an immediate revenue play, the expansion reflects a build-first strategy. CoSara is actively developing distribution channels across the newly added countries, evaluating regulatory pathways, identifying key customer segments, and forming partnerships with regional distributors. Management is also planning a series of engagement initiatives, including a virtual distributor session in the second quarter of 2026 followed by in-person training later in the year.
The opportunity is substantial. South Asia represents one of the fastest-growing markets for molecular diagnostics, driven by rising demand for accessible, rapid, and non-invasive testing for conditions such as tuberculosis, HPV, and respiratory infections. Expanding into these markets’ positions CoSara to address gaps in healthcare infrastructure while increasing access to point-of-care testing solutions.
For Co-Diagnostics, the move fits into a broader global strategy centered on localized manufacturing and distribution hubs. By establishing infrastructure in advance of full product rollout, across regions including South Asia, the United States, and the Middle East and North Africa, the company aims to enable scalable deployment of its diagnostic technologies while reducing barriers to adoption.
The expansion also underscores a key theme in the diagnostics space: success increasingly depends not just on innovation, but on distribution, regulatory execution, and regional presence. By investing early in those capabilities, Co-Diagnostics is positioning itself to compete more effectively as demand for decentralized testing continues to grow.
While near-term financial impact will depend on regulatory timelines and partner execution, the strategic intent is clear, capture share in high-growth international markets by building the infrastructure before the demand fully materializes.
